The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Defining and identifying ultra-high-risk multiple myeloma
Martin Kaiser, MD, FRCP, FRCPath, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, UK, discusses ultra-high-risk multiple myeloma, commenting on the evolution of its definition. Although difficult to define, at present, ultra-high-risk myeloma is considered to be a form of disease characterized by the co-occurrence of several high-risk cytogenetic markers and which is not overcome by novel triplet therapy approaches. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Karyopharm: Consultancy; Celgene/BMS: Consultancy, Honoraria, Research Funding; Takeda: Honoraria; Seagen: Consultancy; Pfizer: Consultancy; Regeneron: Consultancy; Janssen: Consultancy, Honoraria; GSK: Consultancy.
